• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

PRESSLED

Your Leading News Source

PRESSLED
Your Leading News Source

  • Home
  • BUSINESS
  • MONEY
  • POLITICS
  • REAL ESTATE
  • US
  • Meet the Reporters
  • About/Contact

Q&A: Inside the latest cannabis company listing

May 27, 2021 by Staff Reporter

The week after the firm became one of the first weed companies to list in London, Neil Mahapatra, founder and chairman of Oxford Cannabinoid Technologies, sits down with Financial News to answer some quickfire questions.

FN: Why did you pick London for the listing?

NM: There were a couple of reasons. The first is that we are a British company. We began as we signed a research agreement with Oxford University, so when the Financial Conduct Authority announced that the London Stock Exchange would be willing to consider the right type of cannabis business — medicinal rather than recreational — it just felt like a natural fit. We are really pleased to be listing in London; going international would have felt strange.

FN: How was dealing with the regulators in such a new market?

NM: The LSE and the FCA handled themselves in a very professional fashion. They were right to consider things rigorously and deeply. In all our interactions with the regulators on our listing, they’ve been very straightforward and user friendly; it was a pleasure to deal with them.

READ London set for flurry of cannabis IPOs after UK watchdog green light

FN: We’ve heard a lot about retail investors piling into weed stocks, but how has the uptake been with the institutional crowd?

NM: A few institutions have participated in our IPO, and I feel privileged and lucky to have them on board. They are patient, on the board for the journey, which is a 10-year journey. It’s a nice mix of high-net-worth, retail and institutional investors, and I think the reason we have that is that there were two business models we could have chosen: unlicensed medicines, which most medical cannabis firms are and struggle to get the confidence of the medical and institutional community behind them, and licensed, where you progress through pharmaceutical channels that have been around for decades. We found a way to build confidence with everyone you deal with.

FN: Did anyone talk about how a cannabis stock would sit in an ESG portfolio?

NM: We haven’t had that discussion explicitly, but all that being said, we are a healthcare business to develop licensed medication for pain with the backdrop of the opioid crisis. We absolutely believe we are doing a social good so we do fit in the ESG lens. Our board also has an incredible diversity of skill set and personality, so it’s not overtly discussed but would be fair to say we fit.

READ How to invest in cannabis stocks

FN: With so few listings to look back on, how did you decide on a valuation and how much you were going to raise?

The use of proceeds was very clear for us. We have four drug development programs underway. When it came to deciding how much we wanted to raise, the question was how much does it cost to develop all of these programs further? We were oversubscribed, but we didn’t increase the amount we wanted to take as a result.

With regards to valuation, we were very rigorous, looking at risk adjusted returns for drug candidates and discounted it back. It’s always a difficult one when you’re one of the first to list but tools from other sectors can come into play.

FN: Will we get to a stage where cannabis investments are genuinely mainstream? If so, do you think there will be any pushback when people find out that they are in their pension funds, say?

NM: In time they will [become mainstream]. You’re already seeing an increasing amount of institutions starting to look at this. There will be a few trigger points. The first will be federal legalisation in the US, which I very much feel is a matter of time, and once that happens I think that will trigger a wave across the rest of the world of acceptability.

We’re in the business of saving lives it seems like it’s a matter of time before it’s more widely accepted institutionally and were privileged to be part of the tip of the spear driving that. More companies are coming to the market every day and that can only be good for the sector.

To contact the author of this story with feedback or news, email Justin Cash

>>>ad: Don't Miss TODAY'S BEST Amazon Deals!

Originally Appeared Here

Filed Under: BUSINESS, MONEY

Primary Sidebar

More to See

N.J. town votes to let redevelopment of former Lord & Taylor site move forward

The Westfield Town Council voted 7-1 on Tuesday to introduce an ordinance that allows for a downtown redevelopment plan to move forward.It will next … [Read More...] about N.J. town votes to let redevelopment of former Lord & Taylor site move forward

Bed Bath and Beyond is closing 87 more stores. See the list

New York CNN  —  Bed Bath and Beyond is closing another 87 stores as the struggling retailer barrels toward bankruptcy. … [Read More...] about Bed Bath and Beyond is closing 87 more stores. See the list

U.S. launches high-level defense and tech initiative with India

Comment on this storyCommentThe United States and India on Tuesday formally established a high-level initiative on defense and emerging technologies — … [Read More...] about U.S. launches high-level defense and tech initiative with India

Privacy Policy | Terms and Conditions | About/ Contact
Copyright © 2023 · PRESSLED · As Amazon Associates we earn commissions from qualifying purchases · Log in

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT